Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
Laura C CoatesRobert B M LandeweIain B McInnesPhillip J MeaseChristopher T RitchlinYoshiya TanakaAkihiko AsahinaFrank BehrensDafna D GladmanLaure GossecAna Maria OrbaiAlice B GottliebRichard B WarrenBarbara InkRajan BajracharyaVishvesh ShendeJason CoarseJoseph F MerolaPublished in: RMD open (2024)
Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from week 16 to 52.